List view / Grid view

Microbiome therapeutics: microscope to medicine

 

Microbiome therapeutics: microscope to medicine’With insight from industry leaders, this exclusive online monthly series explores the key developments, challenges and opportunities of microbiome therapeutics, spanning a range of topics from clinical stage development though to manufacturing, regulation and quality control in the pharmaceutical industry.

Increasing prevalence of conditions such as metabolic, gastrointestinal and infectious diseases in recent years has resulted in greater interest in digestive health from both the public and pharmaceutical industry, heightening the demand for microbiome therapeutics such as live biotherapeutic products (LBPs) and faecal matter transplants (FMT) treatments.

article

Developing the EU’s first intestinal microbiota-based biologic

12 June 2024 | By

In this final installment of EPR's Microbiome therapeutics: microscope to medicine, Dr Olaia Aurtenetxe, Head of Clinical Research at Mikrobiomik, reveals study data demonstrating why MBK-01, an investigational drug based on faecal microbiota transplantation, presents a promising alternative to the current standard of care for Clostridioides difficile infections (CDI), potentially…

article

Advancing microbiome innovation

10 April 2024 | By

In the fourth instalment of EPR's ‘Microbiome therapeutics: microscope to medicine’ series, Emilie Plantamura, Deputy Chief Medical Officer at MaaT Pharma, examines the promising potential of microbiome therapeutics beyond Clostridium difficile infection, particularly in the onco-haematological field.